JP2010514702A - 食道障害の治療方法および治療用組成物 - Google Patents

食道障害の治療方法および治療用組成物 Download PDF

Info

Publication number
JP2010514702A
JP2010514702A JP2009543271A JP2009543271A JP2010514702A JP 2010514702 A JP2010514702 A JP 2010514702A JP 2009543271 A JP2009543271 A JP 2009543271A JP 2009543271 A JP2009543271 A JP 2009543271A JP 2010514702 A JP2010514702 A JP 2010514702A
Authority
JP
Japan
Prior art keywords
less
proton pump
composition
pump inhibitor
bile acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009543271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514702A5 (https=
Inventor
ジー． カリー，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of JP2010514702A publication Critical patent/JP2010514702A/ja
Publication of JP2010514702A5 publication Critical patent/JP2010514702A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009543271A 2006-12-22 2007-12-21 食道障害の治療方法および治療用組成物 Pending JP2010514702A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87149906P 2006-12-22 2006-12-22
PCT/US2007/088624 WO2008080092A2 (en) 2006-12-22 2007-12-21 Compositions comprising bile acid sequestrants for treating esophageal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015016788A Division JP6141891B2 (ja) 2006-12-22 2015-01-30 食道障害の治療方法および治療用組成物

Publications (2)

Publication Number Publication Date
JP2010514702A true JP2010514702A (ja) 2010-05-06
JP2010514702A5 JP2010514702A5 (https=) 2011-02-10

Family

ID=39277294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009543271A Pending JP2010514702A (ja) 2006-12-22 2007-12-21 食道障害の治療方法および治療用組成物
JP2015016788A Expired - Fee Related JP6141891B2 (ja) 2006-12-22 2015-01-30 食道障害の治療方法および治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015016788A Expired - Fee Related JP6141891B2 (ja) 2006-12-22 2015-01-30 食道障害の治療方法および治療用組成物

Country Status (19)

Country Link
US (4) US9205094B2 (https=)
EP (4) EP2124884B1 (https=)
JP (2) JP2010514702A (https=)
AU (1) AU2007336731B2 (https=)
CA (1) CA2673665C (https=)
CY (1) CY1122009T1 (https=)
DK (1) DK2124884T3 (https=)
ES (1) ES2739542T3 (https=)
HU (1) HUE046465T2 (https=)
IL (1) IL199477A (https=)
LT (1) LT2124884T (https=)
NZ (2) NZ578204A (https=)
PL (1) PL2124884T3 (https=)
PT (1) PT2124884T (https=)
RU (3) RU2491075C2 (https=)
SI (1) SI2124884T1 (https=)
TR (1) TR201910825T4 (https=)
WO (1) WO2008080092A2 (https=)
ZA (1) ZA200904573B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012102362A1 (ja) * 2011-01-27 2012-08-02 興和株式会社 水難溶性薬物含有医薬組成物
JP2016508992A (ja) * 2013-01-15 2016-03-24 アイロンウッド ファーマシューティカルズ，インコーポレーテッドＩｒｏｎｗｏｏｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
JP2017518349A (ja) * 2014-06-20 2017-07-06 メリンタ セラピューティクス インコーポレイテッド 発泡剤を含む抗微生物組成物
JP2022033766A (ja) * 2016-11-02 2022-03-02 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124884B1 (en) 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
ITRM20120041A1 (it) * 2012-02-08 2013-08-09 Dicofarm Spa "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo"
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
RU2667651C1 (ru) * 2017-12-26 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения эрозивной формы гастроэзофагеальной рефлюксной болезни у пациентов, получающих химиотерапию
WO2020077186A1 (en) * 2018-10-12 2020-04-16 Icahn School Of Medicine At Mount Sinai Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions
EP4135740A4 (en) * 2020-04-16 2024-05-22 The Medical College of Wisconsin, Inc. AEROSOL FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY REFLUX

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
JPS53113007A (en) * 1977-03-10 1978-10-03 Reckitt & Colmann Prod Ltd Pharmaceutical composition
JPH0597677A (ja) * 1991-04-12 1993-04-20 Alfa Wassermann Spa 胆汁酸およびその塩を含有する経口投与用の放出制御型胃液耐性製剤
JP2004099612A (ja) * 2002-09-04 2004-04-02 Rohm & Haas Co 上部消化管炎症の緩和

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
DE2704425C2 (de) * 1977-02-03 1982-10-07 Interx Research Corp., 66044 Lawrence, Kan. Verwendung von Styrol-Divinylbenzol-Copolymer-Anionenaustauscherharzen bei der Bekämpfung von Magengeschwüren
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5692217A (en) 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
AU545463B2 (en) 1982-06-25 1985-07-18 Kowa Co. Ltd. Benzoyl piperacine esters
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4738975A (en) 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
FI96860C (fi) 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
JP2916205B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
JP2916206B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
DK223790D0 (da) 1990-09-18 1990-09-18 Novo Nordisk As Proteaseholdig detergentkomposition
US5312824A (en) 1990-10-17 1994-05-17 Takeda Chemical Industries, Ltd. Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers
US5167483A (en) 1990-12-24 1992-12-01 Gardiner Samuel W Method for utilizing angular momentum in energy conversion devices and an apparatus therefore
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5670163A (en) 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19534996A1 (de) 1995-09-21 1997-03-27 Bosch Gmbh Robert Verfahren zur Verbrennungsaussetzererkennung durch Auswertung von Drehzahlschwankungen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6638498B2 (en) 2000-06-30 2003-10-28 Semorex Inc. Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
EP1307263B1 (en) 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag New use of lipase inhibitors
RU2241462C2 (ru) * 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
MXPA03011096A (es) * 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20050202090A1 (en) 2002-01-03 2005-09-15 Clarke Allan J. Novel pharmaceutical dosage forms and method for producing same
BR0308517A (pt) * 2002-03-18 2005-02-01 Pharmacia Corp Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
WO2004002445A2 (en) 2002-06-26 2004-01-08 Cadila Healthcare Limited Novel floating dosage form
KR20050083750A (ko) 2002-10-11 2005-08-26 디포메드 디벨롭먼트 리미티드 위-체류성 레보도파 전달 형태
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2005079752A2 (en) 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
CA2560927C (en) * 2004-03-26 2013-05-14 Mitsubishi Pharma Corporation Insulin resistance-improving agent
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
EP1802287A2 (en) 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
WO2006088305A1 (en) * 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20070269512A1 (en) 2006-05-22 2007-11-22 Wang Wenhua W Gastroretentive sustained release formulations
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2124884B1 (en) 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2009158625A2 (en) 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
JPS53113007A (en) * 1977-03-10 1978-10-03 Reckitt & Colmann Prod Ltd Pharmaceutical composition
JPH0597677A (ja) * 1991-04-12 1993-04-20 Alfa Wassermann Spa 胆汁酸およびその塩を含有する経口投与用の放出制御型胃液耐性製剤
JP2004099612A (ja) * 2002-09-04 2004-04-02 Rohm & Haas Co 上部消化管炎症の緩和

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5010002058; ＲＩＣＨＴＥＲ　ＪＯＥＬ　Ｅ: ＣＵＲＲＥＮＴ　ＴＲＥＡＴＭＥＮＴ　ＯＰＴＩＯＮＳ　ＩＮ　ＧＡＳＴＲＯＥＮＴＥＲＬＯＧＹ Ｖ７　Ｎ１, 2004, Ｐ５３-５８, ＣＵＲＲＥＮＴ　ＳＣＩＥＮＣＥ *
JPN7014000489; Ｃａｒｄｉｏｖａｓｃｕｌａｒ　Ｄｒｕｇ　Ｒｅｖｉｅｗｓ Ｖｏｌ．２３, 2005, ｐ．１５-３０ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012102362A1 (ja) * 2011-01-27 2012-08-02 興和株式会社 水難溶性薬物含有医薬組成物
KR20140005930A (ko) * 2011-01-27 2014-01-15 코와 가부시키가이샤 수난용성 약물 함유 의약 조성물
JPWO2012102362A1 (ja) * 2011-01-27 2014-06-30 興和株式会社 水難溶性薬物含有医薬組成物
KR101947198B1 (ko) 2011-01-27 2019-02-12 코와 가부시키가이샤 수난용성 약물 함유 의약 조성물
JP2016508992A (ja) * 2013-01-15 2016-03-24 アイロンウッド ファーマシューティカルズ，インコーポレーテッドＩｒｏｎｗｏｏｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
JP2018203787A (ja) * 2013-01-15 2018-12-27 アイロンウッド ファーマシューティカルズ，インコーポレーテッドＩｒｏｎｗｏｏｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
JP2017518349A (ja) * 2014-06-20 2017-07-06 メリンタ セラピューティクス インコーポレイテッド 発泡剤を含む抗微生物組成物
JP2020183415A (ja) * 2014-06-20 2020-11-12 メリンタ サブシディアリー コーポレイション 発泡剤を含む抗微生物組成物
JP6995479B2 (ja) 2014-06-20 2022-01-14 メリンタ サブシディアリー コーポレイション 発泡剤を含む抗微生物組成物
JP7149991B2 (ja) 2014-06-20 2022-10-07 メリンタ サブシディアリー コーポレイション 発泡剤を含む抗微生物組成物
JP2022033766A (ja) * 2016-11-02 2022-03-02 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ

Also Published As

Publication number Publication date
RU2705364C2 (ru) 2019-11-07
JP2015212250A (ja) 2015-11-26
WO2008080092A8 (en) 2009-03-05
EP2478894A3 (en) 2012-12-19
CY1122009T1 (el) 2020-10-14
SI2124884T1 (sl) 2019-09-30
LT2124884T (lt) 2019-08-26
TR201910825T4 (tr) 2019-08-21
RU2019134181A (ru) 2021-04-26
EP2478894A2 (en) 2012-07-25
EP2124884A2 (en) 2009-12-02
PL2124884T3 (pl) 2020-01-31
US9205094B2 (en) 2015-12-08
NZ598728A (en) 2013-09-27
EP2124884B1 (en) 2019-07-10
EP2478895A3 (en) 2012-12-19
RU2009128202A (ru) 2011-01-27
JP6141891B2 (ja) 2017-06-07
US20180235878A1 (en) 2018-08-23
US20160051577A1 (en) 2016-02-25
CA2673665A1 (en) 2008-07-03
AU2007336731B2 (en) 2013-08-29
DK2124884T3 (da) 2019-08-05
RU2013117758A (ru) 2014-10-27
ZA200904573B (en) 2010-09-29
AU2007336731A1 (en) 2008-07-03
WO2008080092A2 (en) 2008-07-03
EP3628307A1 (en) 2020-04-01
US20170290767A1 (en) 2017-10-12
EP2478895A2 (en) 2012-07-25
NZ578204A (en) 2012-05-25
PT2124884T (pt) 2019-09-17
IL199477A (en) 2017-07-31
ES2739542T3 (es) 2020-01-31
HUE046465T2 (hu) 2020-03-30
WO2008080092A3 (en) 2008-11-20
CA2673665C (en) 2017-03-21
US20100179235A1 (en) 2010-07-15
RU2491075C2 (ru) 2013-08-27
AU2007336731A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
JP6141891B2 (ja) 食道障害の治療方法および治療用組成物
US20220370367A1 (en) Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant
US20130129660A1 (en) Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
HK1173677A (en) Compositions for treating esophageal disorders
HK1173676A (en) Compositions for treating esophageal disorders
HK1214529B (en) Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140930